247 related articles for article (PubMed ID: 31108181)
21. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.
Brennan PJ; Rodriguez Bouza T; Hsu FI; Sloane DE; Castells MC
J Allergy Clin Immunol; 2009 Dec; 124(6):1259-66. PubMed ID: 19910036
[TBL] [Abstract][Full Text] [Related]
22. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment.
Madrigal-Burgaleta R; Berges-Gimeno MP; Angel-Pereira D; Ferreiro-Monteagudo R; Guillen-Ponce C; Pueyo C; Gomez de Salazar E; Alvarez-Cuesta E
Allergy; 2013 Jul; 68(7):853-61. PubMed ID: 23647576
[TBL] [Abstract][Full Text] [Related]
23. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions.
Picard M; Pur L; Caiado J; Giavina-Bianchi P; Galvão VR; Berlin ST; Campos SM; Matulonis UA; Castells MC
J Allergy Clin Immunol; 2016 Apr; 137(4):1154-1164.e12. PubMed ID: 26725998
[TBL] [Abstract][Full Text] [Related]
24. One-Bag 8-Step Ferric Carboxymaltose Desensitization Protocol for Patients with a History of Hypersensitivity Reactions to Iron Preparations.
Özden Ş; Tepetam FM; Atik Ö
Int Arch Allergy Immunol; 2024; 185(5):449-455. PubMed ID: 38272014
[TBL] [Abstract][Full Text] [Related]
25. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
[TBL] [Abstract][Full Text] [Related]
26. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization.
Castells M; Sancho-Serra Mdel C; Simarro M
Cancer Immunol Immunother; 2012 Sep; 61(9):1575-84. PubMed ID: 22576054
[TBL] [Abstract][Full Text] [Related]
27. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT
J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233
[TBL] [Abstract][Full Text] [Related]
28. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.
Picard M; Castells MC
Clin Rev Allergy Immunol; 2015 Oct; 49(2):177-91. PubMed ID: 24740483
[TBL] [Abstract][Full Text] [Related]
29. Rechallenges without desensitization following platinum-based chemotherapy reactions.
Young FD; Aung S; Tang M; Anstey KM; Lee MC; Alfaro E; Cinar P; Ho H; Otani IM
J Oncol Pharm Pract; 2024 Apr; 30(3):572-575. PubMed ID: 38347725
[TBL] [Abstract][Full Text] [Related]
30. Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity.
Alonso Martinez S; Segal NH; Cercek A; Yaeger R; Stadler Z; Kemeny NE; Nusrat M; Shahrokni A; Connell L; Saltz LB
Clin Colorectal Cancer; 2022 Jun; 21(2):149-153. PubMed ID: 35125319
[TBL] [Abstract][Full Text] [Related]
31. A Large Single-Hospital Experience Using Drug Provocation Testing and Rapid Drug Desensitization in Hypersensitivity to Antineoplastic and Biological Agents.
Madrigal-Burgaleta R; Bernal-Rubio L; Berges-Gimeno MP; Carpio-Escalona LV; Gehlhaar P; Alvarez-Cuesta E
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):618-632. PubMed ID: 30098410
[TBL] [Abstract][Full Text] [Related]
32. Does Rapid Drug Desensitization to Chemotherapy Affect Survival Outcomes?
Berges-Gimeno MP; Carpio-Escalona LV; Longo-Muñoz F; Bernal-Rubio L; Lopez-Gonzalez P; Gehlhaar P; Pachon V; Ferreiro-Monteagudo R; Madrigal-Burgaleta R; Alvarez-Cuesta E
J Investig Allergol Clin Immunol; 2020; 30(4):254-263. PubMed ID: 31188129
[TBL] [Abstract][Full Text] [Related]
33. Hypersensitivity Reactions to Platinum Agents and Taxanes.
Tsao LR; Young FD; Otani IM; Castells MC
Clin Rev Allergy Immunol; 2022 Jun; 62(3):432-448. PubMed ID: 34338975
[TBL] [Abstract][Full Text] [Related]
34. Rapid desensitization of hypersensitivity reactions to chemotherapy agents.
Castells M
Curr Drug Saf; 2006 Aug; 1(3):243-51. PubMed ID: 18690934
[TBL] [Abstract][Full Text] [Related]
35. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy.
Wang AL; Patil SU; Long AA; Banerji A
Ann Allergy Asthma Immunol; 2015 Nov; 115(5):422-8. PubMed ID: 26298407
[TBL] [Abstract][Full Text] [Related]
36. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.
Wong JT; Ling M; Patil S; Banerji A; Long A
J Allergy Clin Immunol Pract; 2014; 2(1):40-5. PubMed ID: 24565767
[TBL] [Abstract][Full Text] [Related]
37. Outcome of 490 Desensitizations to Chemotherapy Drugs with a Rapid One-Solution Protocol.
Pérez-Rodríguez E; Martínez-Tadeo JA; Pérez-Rodríguez N; Hernández-Santana G; Callero-Viera A; Rodríguez-Plata E; García-Robaina JC
J Allergy Clin Immunol Pract; 2018; 6(5):1621-1627.e6. PubMed ID: 29361511
[TBL] [Abstract][Full Text] [Related]
38. A One-Bag Rapid Desensitization Protocol for Paclitaxel Hypersensitivity: A Noninferior Alternative to a Multi-Bag Rapid Desensitization Protocol.
Lee JH; Moon M; Kim YC; Chung SJ; Oh J; Kang DY; Lee SY; Lee KH; Yun J; Kang HR
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):696-703. PubMed ID: 31678295
[TBL] [Abstract][Full Text] [Related]
39. Utility of Risk Stratification for Paclitaxel Hypersensitivity Reactions.
Otani IM; Lax T; Long AA; Slawski BR; Camargo CA; Banerji A
J Allergy Clin Immunol Pract; 2018; 6(4):1266-1273.e2. PubMed ID: 28986119
[TBL] [Abstract][Full Text] [Related]
40. Oxaliplatin-induced hypersensitivity reactions: risk factors and management.
Selcuk A; Yıldız B
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(6):2640-2645. PubMed ID: 37013782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
